Correction: Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis - Report - MDSpire

Correction: Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis

  • By

  • Laís dos Santos

  • Thaís Martins Shehan

  • Candela Lang

  • Ricardo Sanchez Algarin

  • Ingrid Bezerra de Oliveira Ribeiro

  • Paulo Cesar Mattos Dourado de Mesquita

  • Guilherme Dagostin de Carvalho

  • July 4, 2026

  • 0 min

Share

Clinical Report: Correction: A Systematic Review and Meta-Analysis on Adenosine Administration and Cardioversion in Children with Supraventricular Tachycardia

Overview

This correction addresses the author contributions for a systematic review and meta-analysis on adenosine administration and cardioversion in pediatric supraventricular tachycardia (SVT).

Background

Supraventricular tachycardia (SVT) is the most common arrhythmia in children, with significant implications for treatment and management. Intravenous adenosine is a key therapeutic agent used to restore normal heart rhythm in SVT cases.

Data Highlights

No numerical data or trial results are presented in the correction.

Key Findings

  • SVT is prevalent in the pediatric population, occurring in 1 in 250 to 1 in 1000 children.
  • Adenosine is used to temporarily inhibit atrioventricular nodal conduction in SVT treatment.
  • Author contributions have been clarified to ensure transparency in the systematic review.
  • Related studies indicate a dose-response relationship between adenosine and successful cardioversion in children.
  • Current guidelines recommend adenosine administration following ineffective vagal maneuvers in hemodynamically stable SVT cases.

Clinical Implications

Clinicians should be aware of the dosing guidelines for adenosine in treating pediatric SVT.

Conclusion

This correction clarifies the author contributions in clinical research.

Related Resources & Content

  1. L.S., T.M.S., G.D.C., et al., Pediatric Cardiology, 2026 -- Correction: A Systematic Review and Meta-Analysis on Adenosine Administration and Cardioversion in Children with Supraventricular Tachycardia
  2. Pediatric Cardiology — Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis
  3. Pediatric Cardiology — Comparative Analysis of Epicardial and Endocardial Pacing in Children with Atrioventricular Block or Sinus Node Dysfunction: A Systematic Review and Meta-analysis
  4. Pediatric Cardiology — Management of Antiarrhythmic Therapy for Supraventricular Tachycardia in Neonates and Infants
  5. Pediatric Cardiology — Effectiveness of Anti-Arrhythmic Medications in Pediatric Patients with Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes and Potential Asymptomatic Ventricular Tachycardia: A Retrospective Multi-Center Analysis
  6. Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis
  7. The Pediatric Tachycardia With a Pulse Algorithm
  8. Safety of adenosine for pediatric tachyarrhythmia treatment in the emergency department: a multi-hospital 10-year cross-sectional study | International Journal of Emergency Medicine | Springer Nature Link

Original Source(s)

Correction: Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis

  • by Laís dos Santos, Thaís Martins Shehan, Candela Lang, Ricardo Sanchez Algarin, Ingrid Bezerra de Oliveira Ribeiro, Paulo Cesar Mattos Dourado de Mesquita, Guilherme Dagostin de Carvalho

  • July 4, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Clinical Spectrum, independent risk factors, and treatment outcomes of pediatric arrhythmias: a multicenter retrospective analysis in Xinjiang

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.